StocksTelegraph
S&P 500—NASDAQ—DOW—RUSSELL—
NASDAQ · IMNN·Healthcare

Imunon, Inc. Stock Analysis & AI Score

Imunon, Inc. (IMNN) has an ST Score of 36.2 (C), driven by its Growth (A+) and held back by its Profitability (F). Analysts rate it Buy with a $10.00 price target (+640.7% upside).

Market Closed
$1.35
Prev Close
—
Market Cap
—
Day Range
—
52W Range
—
P/E
—
EPS (TTM)
—
Volume
—
Avg —
Beta
—
36
ST Score
36.2/100C

Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.

As of
AI Daily Briefing
Analysis by AI
Price History
—
Technical Indicators
FMP
Earnings Surprises
Analyst Forecast
Revenue Mix

Company Information

Employees—
CEO—
SectorHealthcare
IndustryBiotechnology
IPO Date—
Website—
Country—
ExchangeNASDAQ

SEC Filings

Annual Report (10-K)

Filing DateAcceptedLink
Loading…

Quarterly Report (10-Q)

Filing DateAcceptedLink
Loading…
Analyst Price Target
ESG Score
Latest News

ST Score

IMNN
36.2out of 100
Grade C

Imunon, Inc. (IMNN) has an ST Score of 36.2 (C), driven by its Growth (A+) and held back by its Profitability (F). Analysts rate it Buy with a $10.00 price target (+640.7% upside).

Strongest
GrowthA+
Weakest
ProfitabilityF
All factor grades
  • GrowthA+
  • ForecastA
  • ValuationC+
  • Financial StrengthD-
  • MomentumD-
  • ProfitabilityF
  • Piotroski1/9
Score methodology
Press Releases

Contact

IMNN stock: frequently asked questions

What is IMNN's ST Score?

Imunon, Inc. (IMNN) has an ST Score of 36.2 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Is IMNN a buy, hold, or sell?

Analysts rate IMNN a Buy, with a price target of $10.00 (+640.7% vs the current price). Our ST Score grades it C (36.2/100). The ST Score is a data-driven signal, not a recommendation.

What are IMNN's factor grades?

Valuation C+, Profitability F, Financial Strength D-, Momentum D-, Growth A+, Forecast A.

What is IMNN's valuation grade?

Imunon, Inc. (IMNN) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

What is IMNN's growth grade?

Imunon, Inc. (IMNN) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

What is IMNN's profitability grade?

Imunon, Inc. (IMNN) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

What is IMNN's financial strength grade?

Imunon, Inc. (IMNN) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

What is the analyst price target for IMNN?

The average analyst price target for Imunon, Inc. (IMNN) is $10.00 from 4 analysts, which is +640.7% versus the recent price of $1.35.

What is IMNN's Piotroski score?

Imunon, Inc. (IMNN) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.